Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2022 Filed Sep 1, 2022 20:02 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 28 | $45.23 | $1,266.44 |
DisclosureSEC source: 0001225208-22-009897 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,404 Underlying: Common Stock · 28 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 20:02 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $45.23 | $180.92 |
DisclosureSEC source: 0001225208-22-009898 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,303 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 19:43 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $49.75 | $497.50 |
DisclosureSEC source: 0001225208-22-009598 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,476 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 19:43 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 26 | $49.75 | $1,293.50 |
DisclosureSEC source: 0001225208-22-009599 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,348 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 19:43 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $49.75 | $149.25 |
DisclosureSEC source: 0001225208-22-009600 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 29, 2022 Filed Aug 1, 2022 19:41 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $50.51 | $505.10 |
DisclosureSEC source: 0001225208-22-009085 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,461 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 29, 2022 Filed Aug 1, 2022 19:42 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 25 | $50.51 | $1,262.75 |
DisclosureSEC source: 0001225208-22-009086 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,322 Underlying: Common Stock · 25 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 29, 2022 Filed Aug 1, 2022 19:42 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $50.51 | $151.53 |
DisclosureSEC source: 0001225208-22-009087 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,286 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 16:39 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $51.75 | $517.50 |
DisclosureSEC source: 0001225208-22-008813 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,686 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 16:39 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 25 | $51.75 | $1,293.75 |
DisclosureSEC source: 0001225208-22-008814 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,150 Underlying: Common Stock · 25 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 16:40 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $51.75 | $155.25 |
DisclosureSEC source: 0001225208-22-008815 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,224 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2022 Filed Jul 14, 2022 22:17 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 38 | $51.79 | $1,968.02 |
DisclosureSEC source: 0001225208-22-008780 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,672 Underlying: Common Stock · 38 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2022 Filed Jul 14, 2022 22:17 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 112 | $51.79 | $5,800.48 |
DisclosureSEC source: 0001225208-22-008781 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,124 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2022 Filed Jul 14, 2022 22:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 15 | $51.79 | $776.85 |
DisclosureSEC source: 0001225208-22-008782 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,221 Underlying: Common Stock · 15 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 03, 2022 Filed Jul 5, 2022 20:53 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 866.427 | $52.31 | $45,322.80 |
DisclosureSEC source: 0001225208-22-008508 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,441.263 Underlying: Common Stock · 866.427 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · price: Price is the closing price of Pfizer common stock on July 1, 2022. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| July 03, 2022 Filed Jul 5, 2022 20:53 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 938.115 | $52.31 | $49,072.80 |
DisclosureSEC source: 0001225208-22-008509 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,825.069 Underlying: Common Stock · 938.115 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · price: Price is the closing price of Pfizer common stock on July 1, 2022. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| July 03, 2022 Filed Jul 5, 2022 20:53 UTC |
Quincey JamesDirector
|
GrantPhantom Stock Units · Derivative | 723.051 | $52.31 | $37,822.80 |
DisclosureSEC source: 0001225208-22-008510 · doc4.xml · derivative · entry 1 Quincey James · CIK 0001561264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,961.383 Underlying: Common Stock · 723.051 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · price: Price is the closing price of Pfizer common stock on July 1, 2022. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| July 03, 2022 Filed Jul 5, 2022 20:53 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 842.531 | $52.31 | $44,072.80 |
DisclosureSEC source: 0001225208-22-008511 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,844.662 Underlying: Common Stock · 842.531 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · price: Price is the closing price of Pfizer common stock on July 1, 2022. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:07 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $52.43 | $524.30 |
DisclosureSEC source: 0001225208-22-008397 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,627 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:07 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 25 | $52.43 | $1,310.75 |
DisclosureSEC source: 0001225208-22-008398 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,010 Underlying: Common Stock · 25 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:07 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $52.43 | $157.29 |
DisclosureSEC source: 0001225208-22-008399 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,205 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 18:06 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 11 | $48.51 | $533.61 |
DisclosureSEC source: 0001225208-22-008143 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,651 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 18:07 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 27 | $48.51 | $1,309.77 |
DisclosureSEC source: 0001225208-22-008144 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,993 Underlying: Common Stock · 27 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 18:07 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $48.51 | $194.04 |
DisclosureSEC source: 0001225208-22-008145 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,204 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:43 UTC |
DAMICO JENNIFER B.SVP & Controller
|
SaleCommon Stock | 4,218 | $53.96 | $227,603.28 |
DisclosureSEC source: 0001225208-22-007875 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,846 Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:50 UTC |
Denton David MChief Financial Officer & EVP
|
GrantStock Appreciation Rights · Derivative | 70,313 | $0.00 Strike: $53.04 | $0.00 |
DisclosureSEC source: 0001225208-22-007553 · doc4.xml · derivative · entry 3 Denton David M · CIK 0001428718 · Chief Financial Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,313 Underlying: Common Stock · 70,313 shares Expires 2029-05-31 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:50 UTC |
Denton David MChief Financial Officer & EVP
|
GrantStock Appreciation Rights · Derivative | 80,703 | $0.00 Strike: $53.04 | $0.00 |
DisclosureSEC source: 0001225208-22-007553 · doc4.xml · derivative · entry 2 Denton David M · CIK 0001428718 · Chief Financial Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,703 Underlying: Common Stock · 80,703 shares Expires 2027-05-31 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:50 UTC |
Denton David MChief Financial Officer & EVP
|
GrantCommon Stock | 61,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-007553 · doc4.xml · nonDerivative · entry 1 Denton David M · CIK 0001428718 · Chief Financial Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,165 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:50 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $53.04 | $530.40 |
DisclosureSEC source: 0001225208-22-007554 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,541 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:50 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 24 | $53.04 | $1,272.96 |
DisclosureSEC source: 0001225208-22-007555 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,946 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:51 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $53.04 | $159.12 |
DisclosureSEC source: 0001225208-22-007556 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,194 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 16, 2022 Filed May 17, 2022 11:48 UTC |
DAMICO JENNIFER B.SVP & Controller
|
SaleCommon Stock | 4,000 | $50.50 | $202,000.00 |
DisclosureSEC source: 0001225208-22-007104 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,064 Read SEC document |
| May 13, 2022 Filed May 17, 2022 01:22 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $49.92 | $499.20 |
DisclosureSEC source: 0001225208-22-007093 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,599 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 13, 2022 Filed May 17, 2022 01:22 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $49.92 | $149.76 |
DisclosureSEC source: 0001225208-22-007094 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,196 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 13, 2022 Filed May 17, 2022 01:23 UTC |
SAHNI PAYALExecutive Vice President
|
SaleCommon Stock | 1,408 | $49.84 | $70,174.72 |
DisclosureSEC source: 0001225208-22-007095 · doc4.xml · nonDerivative · entry 1 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,372 Read SEC document |
| May 13, 2022 Filed May 17, 2022 11:48 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 26 | $49.92 | $1,297.92 |
DisclosureSEC source: 0001225208-22-007104 · doc4.xml · derivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,935 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 12, 2022 Filed May 13, 2022 21:19 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 38,273 | $49.41 | $1,891,068.93 |
DisclosureSEC source: 0001225208-22-007018 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,803 Read SEC document |
| May 12, 2022 Filed May 13, 2022 21:38 UTC |
Carapezzi William R JRExecutive Vice President
|
SaleCommon Stock | 32,908 | $50.00 | $1,645,400.00 |
DisclosureSEC source: 0001225208-22-007019 · doc4.xml · nonDerivative · entry 1 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,146 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
SUSMAN SALLYExecutive Vice President
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006908 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,450 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
OtherPhantom Stock Units SSP · Derivative | 15,167 | $49.45 | $750,008.15 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · derivative · entry 8 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 15,167 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: This transaction constitutes an intra-plan transfer into the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 32,015 | $49.31 | $1,578,659.65 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,342 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 18,562 | $49.32 | $915,477.84 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,357 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 7,876 | $49.33 | $388,523.08 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,919 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,891 | $49.35 | $142,670.85 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,795 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,358 | $49.34 | $116,343.72 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,686 Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 200 | $49.36 | $9,872.00 |
DisclosureSEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,044 Read SEC document |
| April 29, 2022 Filed May 2, 2022 20:20 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $49.07 | $490.70 |
DisclosureSEC source: 0001225208-22-006322 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,863 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 29, 2022 Filed May 2, 2022 20:19 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 26 | $49.07 | $1,275.82 |
DisclosureSEC source: 0001225208-22-006323 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,772 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 29, 2022 Filed May 2, 2022 20:19 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $49.07 | $196.28 |
DisclosureSEC source: 0001225208-22-006324 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,137 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:14 UTC |
BLAYLOCK RONALD EDirector
|
GrantPhantom Stock Units · Derivative | 4,058.602 | $50.51 | $204,999.99 |
DisclosureSEC source: 0001225208-22-006285 · doc4.xml · derivative · entry 1 BLAYLOCK RONALD E · CIK 0001214686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,235.927 Underlying: Common Stock · 4,058.602 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.